Cerus Corporation (CERS) Guidance & Earnings Results

On 2026-07-30 Cerus Corporation raised guidance: "FY2026 product revenue guidance raised to $229-231M (11-12% growth); IFC sales outlook raised to $23-25M (+40-50%…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CERSCerus CorporationFollow CERS — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 469.6M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Raised	FY2026 product revenue guidance raised to $229-231M (11-12% growth); IFC sales outlook raised to $23-25M (+40-50% YoY) · full year
30 Apr 26	Raised	Product revenue guidance raised from $224M-$228M to $227M-$231M; IFC guidance raised from $20M-$22M to $22M-$24M · full year
2 Mar 26	Raised	FY2026 product revenue growth 9-11% YoY (excluding government grant revenue)
12 Jan 26	Raised	FY2026 product revenue guidance $224-228M (+9-11% YoY)
6 Nov 25	Raised	Full-year 2025 product revenue guidance raised to $202M-$204M · full year
5 Aug 25	Raised	FY2025 product revenue raised to $200-203M from $195-200M · full year

Cerus Corporation — questions

What guidance did Cerus Corporation give?: On 2026-07-30: "FY2026 product revenue guidance raised to $229-231M (11-12% growth); IFC sales outlook raised to $23-25M (+40-50% YoY)"
When does Cerus Corporation report earnings?: Cerus Corporation's next earnings report is expected on 2026-11-02.

Every figure on this page comes from Cerus Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.